Table 3.

Summary of recommendations on treatment of obstetric-associated venous thromboembolism

	ACCP [12]	ANZJOG [15]	ASH [16]	ESC [19]	GTH [20]	RCOG [24]	SOGC [26]
Pregnant patients
Anticoagulant choice	LMWH, UFH NOACs(×)	LMWH, UFH, VKA (×)	LMWH (prefer), UFH	UFH (high risk) LMWH (low risk)	LMWH (prefer), UFH VKA (×), NOACs (×)	LWMH	LMWH, VKA (×, unless special situation), NOACs (×)
Duration	3 m	6-8 m			3 m	6w-3 m	3 m
Mechanical prophylaxis		Compression stocking 2y					√
Vena cava filters		Acute DVT with contra-indications for anticoagulation				Patients with iliac vein VTE, with proven DVT and recurrent PE	Acute DVT with contra-indications for anticoagulation
Thrombolysis		Only life-threatening DVT	Not recommend		Only life-threatening PE	Massive PE	Only life-threatening DVT
Delivery patients	Discontinuation of LMWH at least 24 h					Intravenous UFH for 24 h
Lactating women
Anticoagulant choice	VKA, UFH, LMWH				Warfarin, LMWH	LMWH, Warfarin (X)
Duration	6w	6w			6w	6w-3 m	6w

ACCP American College of Chest Physicians, ANZJOG Australian and New Zealand Journal of Obstetrics and Gynaecology, ASH American Society of Hematology, DVT Deep Vein Thrombosis, ESC European Society of Cardiology, GTH Working Group in Women’s Health of the Society of Thrombosis and Haemostasis, LMWH Low Molecular Weight Heparin, NOAC Novel Oral Anticoagulants, PE Pulmonary Embolism, RCOG Royal College of Obstetricians and Gynaecologists, SOGC Society of Obstetricians and Gynaecologists of Canada, UFH Unfraction Heparin, VKA Vitamin K antagonist